Cefoxitin |
| Catalog No.GC60686 |
La cefoxitina, un antibiÓtico betalactÁmico, es una cefalosporina de segunda generaciÓn de amplio espectro.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 35607-66-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Cefoxitin is a broad-spectrum, second-generation cephalosporin with antibacterial activity. Cefoxitin is effective against a wide variety of infections caused by gram-positive or gram-negative aerobes as well as by anaerobic bacteria[1][2].
Cefoxitin has good activity against gram-positive bacteria. The MICs for several gram-positive pathogens are in the range of 1-6 μg/mL[1].Cefoxitin has shown high efficacy killing B. burgdorferi at concentration of 1.25 µM/mL[3].
Cefoxitin (20 mg/kg; i.p.; daily; for 5 days) effectively kills B. burgdorferi in vivo C3H/HeN mouse model[3]. Animal Model: Four-week-old female C3H/HeN mice[3]
[1]. E O Stapley, et al. Cefoxitin and cephamycins: microbiological studies. Rev Infect Dis. Jan-Feb 1979;1(1):73-89. [2]. R N Brogden, et al. Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1979 Jan;17(1):1-37. [3]. Venkata Raveendra Pothineni, et al. In vitro and in vivo evaluation of cephalosporins for the treatment of Lyme disease. Drug Des Devel Ther. 2018; 12: 2915-2921.
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *